Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer

Ebrahimi, Nader; Parkhideh, Sahar; Samizade, Setare; Esfahani, Alireza Nasr; Samsami, Sahar; Yazdani, Elnaz; Adelian, Samaneh; Chaleshtori, Siavash Rahimian; shahamiri, kamal; Ahmadi, Amirhossein; Aref, Amir Reza

doi:10.1016/j.cytogfr.2022.04.003

Cited by 25 publications

(8 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, due to their crucial roles in cancer progression and resistance to treatment, lncRNAs are regarded as potential targets for therapeutic strategies in cancer patients. 92 Direct delivery of tumor-suppressive lncRNAs and silencing oncogenic lncRNAs show promise for enhancing cancer treatments, but face challenges like drug toxicity and off-target effects. 93 Therefore, it is crucial to improve the safety and effectiveness of lncRNA-based cancer therapy through the development of better delivery methods.…”

Section: Clinical Implications Of Lncrnas In Chemotherapy Resistancementioning

confidence: 99%

Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

Zhang,

Wu,

Wang

et al. 2024

DDDT

View full text Add to dashboard Cite

In the past few decades, chemotherapy has been one of the most effective cancer treatment options. Drug resistance is currently one of the greatest obstacles to effective cancer treatment. Even though drug resistance mechanisms have been extensively investigated, they have not been fully elucidated. Recent genome-wide investigations have revealed the existence of a substantial quantity of long non-coding RNAs (lncRNAs) transcribed from the human genome, which actively participate in numerous biological processes, such as transcription, splicing, epigenetics, the cell cycle, cell differentiation, development, pluripotency, immune microenvironment. The abnormal expression of lncRNA is considered a contributing factor to the drug resistance. Furthermore, drug resistance may be influenced by genetic and epigenetic variations, as well as individual differences in patient treatment response, attributable to polymorphisms in metabolic enzyme genes. This review focuses on the mechanism of lncRNAs resistance to target drugs in the study of tumors with high mortality, aiming to establish a theoretical foundation for targeted therapy.

show abstract

Section: Clinical Implications Of Lncrnas In Chemotherapy Resistancementioning

confidence: 99%

Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

Zhang,

Wu,

Wang

et al. 2024

DDDT

View full text Add to dashboard Cite

show abstract

“…Abnormal expression of lncRNA is common in a variety of cancers ( 41 ). They have a significant impact on the onset and progression of various malignancies ( 81 , 82 ). According to the findings in Table 2 , a large quantity of lncRNA was shown to involve in PCa bone metastasis.…”

Section: Association Of Lncrna With Pca Bone Metastasismentioning

confidence: 99%

The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system

Sang,

Li,

Zhao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Prostate cancer is a major contributor to male cancer-related mortality globally. It has a particular affinity for the skeletal system with metastasis to bones seriously impacting prognosis. The identification of prostate cancer biomarkers can significantly enhance diagnosis and patient monitoring. Research has found that cancer and metastases exhibit abnormal expression of numerous non-coding RNA. Some of these RNA facilitate prostate cancer bone metastasis by activating downstream signaling pathways, while others inhibit this process. Elucidating the functional processes of non-coding RNA in prostate cancer bone metastasis will likely lead to innovative treatment strategies for this malignant condition. In this review, the mechanistic role of the various RNA in prostate cancer is examined. Our goal is to provide a new avenue of approach to the diagnosis and treatment of bone metastasis in this cancer.

show abstract

“…Additionally, with the application of nascent transcriptomics technology, abundant molecular mechanisms of lncRNAs have been identified ( Nojima and Proudfoot, 2022 ). Mounting evidence demonstrates that lncRNAs play an indispensable role in cancer progression, tumorigenesis, and immune responses ( Bhan et al, 2017 ; Ebrahimi et al, 2022 ; Park et al, 2022 ). For instance, increased lncRNA H19 expression is notably associated with elevated metastasis rates, decreased therapeutic sensitivity and enhanced cancer progression via modulation of numerous targets and molecular pathways, such as RUNX1, STAT3, β-catenin, and FOXM1 in various cancers ( Hashemi et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Prognostic effect of lncRNA BBOX1-AS1 in malignancies: a meta-analysis

Lin,

Wang,

Deng

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: With the increasing number of new cancer cases and mortality rates, cancer has become a serious global health problem, but there are no ideal cancer biomarkers for effective diagnosis. Currently, mounting evidence demonstrates that lncRNAs play a fundamental role in cancer progression. BBOX1 anti-sense RNA 1 (BBOX1-AS1) is a recently clarified lncRNA and has been identified as dysregulated in various carcinomas, and it contributes to poor survival in cancer patients.Methods: We thoroughly searched six databases for eligible articles published as of 27, April 2023. The association of BBOX1-AS1 expression levels with prognostic and clinicopathological parameters was assessed by odds ratios (OR) and hazard ratios with 95% CIs. Additionally, we further validated our results utilizing the GEPIA online database.Results: Eight studies comprising 602 patients were included in this analysis. High BBOX1-AS1 expression indicated poor overall survival (OS) (hazard ratios = 2.30, 95% Cl [1.99, 2.67], p < 0.00001) when compared with low BBOX1-AS1 expression. Furthermore, BBOX1-AS1 expression was positively correlated with lymph node metastasis (OR = 3.00, 95% CI [1.71–5.28], p = 0.0001) and advanced tumor stage (OR = 3.74, 95% CI [2.63–5.32], p < 0.00001) for cancer patients. Moreover, BBOX1-AS1 was remarkably upregulated in 12 malignancies, and the elevated BBOX1-AS1 expression predicted poorer OS and worse disease-free survival (DFS) confirmed through the GEPIA online gene analysis tool.Conclusion: The findings highlight that BBOX1-AS1 was significantly associated with detrimental overall survival, disease-free survival, lymph node metastasis and tumor stage; thus, it could act as a novel promising biomarker to predict the clinicopathological characteristics and prognosis for various cancers.

show abstract

Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer

Cited by 25 publications

References 165 publications

Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm

The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system

Prognostic effect of lncRNA BBOX1-AS1 in malignancies: a meta-analysis

Contact Info

Product

Resources

About